The new figures come just a week after the CDC released its state map of obesity rates around the country, based on results ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Lawmakers are set to scrutinize the high cost of weight loss and diabetes drugs, which depending upon your insurance can ...

Additionally, we expect forced Medicare price negotiations for Wegovy (as part of the Inflation Reduction Act) to also ...

Good evening! The last full-size Kmart store in the United States is closing. On a brighter note, the Philadelphia Phillies ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...

Novo Nordisk CEO Lars Jergensen testified on the company's pricing for its diabetes and weight loss drugs, Ozempic and Wegovy, respectively. Public affairs events, congressional hearings, speeches, ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...